Elevated pre-operative neutrophil to lymphocyte ratio predicts disease free survival following pancreatic resection for periampullary carcinomas

Pancreatology

Volumn 13, Issue 5, 2013, Pages 534-538

  Hamed, Mazin O ^a   Roberts, Keith J ^a   Smith, Andrew M ^a   Stiff, Gareth Morris ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Disease free survival; Neutrophilelymphocyte ratio; Pancreatoduodenectomy; Periampullary carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PERIAMPULLARY CARCINOMA; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VATER PAPILLA CARCINOMA;

DISEASE-FREE SURVIVAL; NEUTROPHIL-LYMPHOCYTE RATIO; PANCREATODUODENECTOMY; PERIAMPULLARY CARCINOMA;

ADENOCARCINOMA; AGED; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84892570559     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2013.07.283     Document Type: Article

References (33)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539e45.
2. Roxburgh CSD, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012; 38(5): 451E66.
3. Richards CH, Flegg KM, Roxburgh CSD, Going JJ, Mohammed Z, Horgan PG, et al. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2010; 106: 12.
4. Macarthur Mairi, Hold Georgina L, El-Omar Emad M. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2003. http: //dx.doi.org/10.1152/ajpgi.00475.
5. Trinchieri Giorgio. Inflammation in cancer: a therapeutic target? Oncology 2011; 25(5).
6. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31e41.
7. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; Sep 1; 91(3): 181e4.
8. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, et al. Elevated pre-operative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34(1): 55E60.
9. Hirashima M, Higuchi S, Sakamoto K, Nishiyama T, Okada H. The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol 1998; 124: 329E34.
10. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Pre-operative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 2: 197e203.
11. Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, Konya V, et al. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology 2010; 57(99e100): 640e5.
12. Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 2007; 9(6): 456E60.
13. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006; 93: 1232E7.
14. Bachmann Jeannine, Michalski Christoph W, Martignoni Marc E, Büchler Markus W, Friess Helmut. Pancreatic resection for pancreatic cancer. HPB (Oxford) 2006; 8(5): 346E51.
15. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006, Jan 30; 94(2): 227e30.
16. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastrooesophageal cancer. Br J Cancer 2006, Mar 13; 94(5): 637e41.
17. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006; 6(5): 450E3.
18. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomy in the 1980s: pathology, complications, and outcomes. Ann Surg 1997; 226: 248e57.
19. Ho Choon-Kiat, Kleeff Jörg, Friess Helmut, Büchler Markus W. Complications of pancreatic surgery. HPB (Oxford) 2005; 7(2): 99E108.
20. Morrison M. Post-pancreatic resection: general overview and unique complications. Dimens Crit Care Nurs 2010; 29(4): 157e62.
21. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68E72.
22. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59E66.
23. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120E4.
24. Smith RA, Bosonnet L, Ghaneh P, Sutton R, Evans J, Healey P, et al. The plateletlymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 2008; 143(5): 658E66.
25. OngSL, Garcea G, Thomasset SC, Mann CD, Neal CP, AbuAmara M, et al. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg 2008; 12: 1068E73.
26. Sakka N, Smith RA, Whelan P, Ghaneh P, Sutton R, Raraty M, et al. A preoperative prognostic score for resected pancreatic and periampullary neuroendocrine tumours. Pancreatology 2009; 9: 670E6.
27. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by pre-operative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008; 12: 1422E8.
28. Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, et al. Serum C-reactive protein and risk of pancreatic cancer in two nested, casecontrol studies. Cancer Epidemiol Biomarkers Prev 2011; 20(2): 359E69.
29. Basso D, Fabris C, Meani A, Del Favero G, Vianello D, Angonese C, et al. C reactive protein in pancreatic cancer and chronic pancreatitis. Ann Clin Res 1988; 20(6): 414E6.
30. Romano F, Uggeri F, Crippa S, Di Stefano G, Scotti M, Scaini A, et al. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res 2004; 23: 195E200.
31. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas e 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567e79.
32. Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65: 618E23.
33. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223: 273E9.